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Abstract
Background: Mucopolysaccharidosis type I (MPS I) is traditionally divided into three phenotypes: the severe Hurler
(MPS I-H) phenotype, the intermediate Hurler-Scheie (MPS I-H/S) phenotype and the attenuated Scheie (MPS I-S)
phenotype. However, there are no clear criteria for delineating the different phenotypes. Because decisions about
optimal treatment (enzyme replacement therapy or hematopoietic stem cell transplantation) need to be made
quickly and depend on the presumed phenotype, an assessment of phenotypic severity should be performed soon
after diagnosis. Therefore, a numerical severity scale for classifying different MPS I phenotypes at diagnosis based
on clinical signs and symptoms was developed.
Methods: A consensus procedure based on a combined modified Delphi method and a nominal group technique
was undertaken. It consisted of two written rounds and a face-to-face meeting. Sixteen MPS I experts participated
in the process. The main goal was to identify the most important indicators of phenotypic severity and include
these in a numerical severity scale. The correlation between the median subjective expert MPS I rating and the
scores derived from this severity scale was used as an indicator of validity.
Results: Full consensus was reached on six key clinical items for assessing severity: age of onset of signs and
symptoms, developmental delay, joint stiffness/arthropathy/contractures, kyphosis, cardiomyopathy and large head/
frontal bossing. Due to the remarkably large variability in the expert MPS I assessments, however, a reliable
numerical scale could not be constructed. Because of this variability, such a scale would always result in patients
whose calculated severity score differed unacceptably from the median expert severity score, which was
considered to be the ‘gold standard’.
Conclusions: Although consensus was reached on the six key items for assessing phenotypic severity in MPS I,
expert opinion on phenotypic severity at diagnosis proved to be highly variable. This subjectivity emphasizes the
need for validated biomarkers and improved genotype-phenotype correlations that can be incorporated into
phenotypic severity assessments at diagnosis.
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Mucopolysaccharidosis type I (MPS I; OMIM #252800)
is a rare autosomal recessive lysosomal storage disorder
caused by a deficiency in the alpha-L-iduronidase
(IDUA) enzyme, which is involved in the breakdown of
the glycosaminoglycans (GAGs) heparan sulfate and der-
matan sulfate [1]. The resulting GAG accumulation
leads to cellular and organ dysfunction. More than 140
different mutations in the IDUA gene have been
described [2,3]. The birth prevalence varies from 1 in
26,000 (in the Irish Republic) to less than 1 in 900,000
(in Taiwan) [4,5].
MPS I is traditionally divided into three phenotypes:
the severe Hurler (MPS I-H) phenotype, the intermedi-
ate Hurler-Scheie (MPS I-H/S) phenotype, and the atte-
nuated Scheie (MPS I/S) phenotype. In reality, however,
MPS I presents with a continuous spectrum of phenoty-
pic severity [1,6,7].
MPS I-H patients have marked cognitive delay, coarse
facial features, corneal clouding, hearing impairment,
ear-nose-throat infections, hepatosplenomegaly, umbili-
cal and inguinal hernias, restricted joint mobility and
orthopedic, cardiac and respiratory problems in early
childhood. Without appropriate treatment, their life
expectancy is severely limited. At the other end of the
spectrum, MPS I-S patients have normal intelligence
and near-normal life expectancy but experience signifi-
cant morbidity as a consequence of restricted joint
mobility, carpal tunnel syndrome, skeletal dysplasia, car-
diac disorders and pulmonary dysfunction. Patients with
the intermediate MPS I-H/S phenotype are generally
described as having no or only mild cognitive impair-
ment and relatively severe somatic symptoms that limit
life expectancy to the 2
nd or 3
rd decade in the absence
of treatment [1,6-9].
Two therapeutic options are currently available: hema-
topoietic stem cell transplantation (HSCT) and intrave-
nous enzyme replacement therapy (ERT). HSCT can
stabilize neurocognitive function, prevent fatal cardio-
pulmonary complications, and improve overall survival
[10]. However, HSCT can only preserve cognitive func-
tion if successfully performed at an early age [10-12],
before the onset of significant central nervous system
involvement, and it still carries a considerable risk of
procedure-related morbidity and mortality. Weekly ERT
with recombinant IDUA (laronidase) can improve the
respiratory and cardiac symptoms and some of the ske-
letal and joint manifestations, reduce hepatosplenome-
galy, and improve the overall quality of life [13-17].
Because intravenously administered laronidase does not
cross the blood-brain barrier [18], ERT cannot prevent
cognitive decline in patients with MPS I-H. Therefore,
HSCT is the preferred treatment strategy for patients
with a presumed MPS 1-H phenotype who are diag-
nosed before the age of approximately 2.5 years, while
patients with the MPS I-H/S and MPS I-S phenotypes
may benefit significantly from ERT [12].
When an MPS I diagnosis is made, the phenotype
needs to be assessed as soon as possible so that the
optimal treatment strategy can be quickly determined.
The outcome of HSCT in MPS I-H is less favorable
when there is a longer delay between diagnosis and
transplant [19,20]. If ERT is the treatment of choice, it
probably should be initiated early to prevent irreversible
damage [12,21]. Because the predictive value of genotyp-
ing is still limited, the phenotypic severity often needs to
be assessed solely on the basis of clinical signs and
symptoms. However, clear criteria for delineating the
different phenotypes are lacking, particularly at the time
of diagnosis.
The aim of this study was to develop a consensus
scale for phenotypically classifying MPS I patients at
diagnosis based on clinical signs and symptoms.
Methods
The process for constructing a diagnostic disease severity
scale included two written rounds, a consensus meeting
and a combined modified Delphi method and nominal
group technique [22,23]. All of the 16 internationally
recognized MPS I experts who were invited to join this
project agreed to collaborate. In the first written round,
the experts were asked to assess the relative importance
of potential criteria for classifying disease severity. For
this purpose, a list of 30 criteria selected from a review of
the literature was composed by three experts (CEH,
FAW and JEW) (Table 1 top panel). The participants
rated the 30 criteria (major, intermediate, minor or
redundant) according to their perceived importance for
phenotypic classification at diagnosis and also proposed
additional criteria. Nine addi t i o n a lc r i t e r i aw e r es u g -
gested (Table 1, bottom panel). Based on these results,
seven items that were rated of major importance by the
majority of the experts and not rated as redundant by
any were selected (’results, first written round’, Table 2).
In the second written round, 20 MPS I case descrip-
tions were sent to the experts. The case descriptions
were based on clinical information available at the time
of diagnosis and were retrieved from two participating
centers (Amsterdam and Manchester). The cases were
selected to represent a wide range of MPS I phenotypes.
The experts rated each case description for severity on
an 11-point scale (0 = mildest; 10 = most severe). If one
of the experts was involved in treating one of the speci-
fic cases, that expert’s rating for that case was excluded
from the analyses. The median expert rating for a case
was considered to be the ‘gold standard’ severity score.
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tor (QGAT) according to the presence or absence of the
39 criteria in Table 1. Mann-Whitney U tests were used
to investigate the associations between the median
expert case scores and the presence or absence of each
of the 39 items. An item was considered to be “key”
when there was a significant difference (p < 0.05)
between the median expert rating of the cases for which
Table 1 The item-pool used for developing the MPS I phenotype severity scale
Items Rated to be of major importance by ≥50% of experts and as
‘redundant’ by none
Not present in any of the 20 patient
descriptions
Included in first written round:
1. Age at onset of symptoms
(historical)
x
2. Age at diagnosis
3. Coarse facial features
4. Abdominal hernia
5. Inguinal hernia
6. Developmental delay x
7. Cognitive decline x x
8. Hydrocephalus x
9. Cervical cord compression x
10. Carpal tunnel syndrome
11. Corneal clouding
12. Elevated ocular pressure x
13. Recurrent upper airway
infections
14. Recurrent otitis media
15. Hearing disorders
16. Pulmonary function
17. Respiratory insufficiency x
18. Obstructive sleep apnea
syndrome
x
19. Valvular heart disease
20. Cardiomyopathy
21. Coronary artery disease x
22. Hepatosplenomegaly
23. Dysostosis multiplex
24. Kyphosis x
25. Hip dysplasia
26. Toe walking x
27. Joint stiffness/arthropathy/
contractures
x
28. Growth retardation
29. Premature death x
30. Dermal melanocytosis x
Proposed as additional items by the
respondents:
31. Positive family history x
32. Hypertrichosis
33. Macroglossia
34. Hypotonia in infancy
35. Protruded sternum
36. Large head/frontal bossing
37. Psychosis x
38. Affected sibling x
39. Early accelerated growth x
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the cases for which the item was not present. The list of
key items resulting from this analysis constituted the
‘results, second written round’ (Table 2).
A face-to-face consensus meeting was subsequently
held in Amsterdam (in May 2008). To investigate the
intra-observer reproducibility [24], all 20 case descrip-
tions were presented in a random order and rated by
the experts for severity again. The experts were then
informed of the results of the two written rounds, and
all of the case descriptions were then separately dis-
cussed. The experts were asked to explain which items
they considered to be most important for assessing dis-
ease severity in a particular case, which led to discus-
sions about which of the items were most important
and how they should be defined. Next, every expert pro-
posed a list of the items they deemed important for a
severity scale. These items were ranked according to the
frequency with which they had been proposed (Table 3)
a n dc o m p a r e dw i t ht h ei t e m si nt h e‘results, second
written round’ (Table 2). Finally, a consensus was
reached on the list of items considered to be most
important for phenotypic classification (’results, consen-
sus meeting’; Table 2).
For the three items in which the severity definition or
grading was complicated, working groups of 3-5 experts
were asked to make a proposal for each item based on
the best evidence.
After the meeting, the scores of the items in the final
consensus list that were present in each patient descrip-
tion were equally weighted and summed to obtain an
objective MPS I phenotypic severity score at diagnosis.
The correlation between the scores on this ‘MPS I
severity scale’ and the median expert scores (’gold stan-
dard’) for the 20 case descriptions was calculated.
To assess the validity of this scale, a set of 18 new
MPS I case descriptions, again representing the full
MPS I phenotypic spectrum, was compiled. Care was
taken to include information on all six of the items in
the final consensus list (Table 2) in each case descrip-
tion. The experts rated the new cases for severity (0-10),
and the correlation between the objective phenotypic
severity scores and the median expert scores for the 18
case descriptions was calculated.
Statistical analysis
The association between the presence or absence of
each item and the median expert severity scores for the
individual cases was investigated using the Mann-Whit-
ney U test (SPSS 18.0). To quantify the intra- and inter-
rater reproducibility of the expert scores, the variance
components were calculated using a three-way random
effects analysis of variance model with the scores as the
dependent variable. The following variance components
were estimated using the model: between patients (sP
2),
between experts (sE
2), between rounds (sR
2), the
Table 2 An overview of results during the different stages of the consensus procedure
’results, 1
st written round’ Considered to be of major
importance by the majority and redundant by none of
the experts
’results, 2
nd written round’ Resulting
from statistical comparisons of the
median expert scores
’results, consensus
meeting’ Final
consensus list
Cognitive decline x
Age at onset of
symptoms
xx x
Developmental
delay
xx x
Hydrocephalus x
Kyphosis x x x
Obstructive sleep
apnea syndrome
x E
Joint stiffness/
arthropathy/
contractures
x x
Large head/
frontal bossing
xx
Early diagnosis x
Dysostosis
multiplex
xE
Coarse facial
features
x
Cardiomyopathy x
Growth
retardation
E
E: excluded from the final severity scale after working group discussions
de Ru et al. Orphanet Journal of Rare Diseases 2012, 7:22
http://www.ojrd.com/content/7/1/22
Page 4 of 9patients × experts interaction (sPE
2), the patients x
rounds interaction (sPR
2), the experts × rounds interac-
tion (sER
2), and the residual (sPER
2). Because the abso-
lute values of the expert scores were not of interest,
intraclass correlation coefficients (ICCs) were calculated
to assess consistency [25].
The intra-rater ICCconsistency was calculated using the
following formula:
ICC =
σ2
P + σ2
PE
σ2
P + σ2
PE + σ2
PR + σ2
PER
The inter-rater ICCconsistency was calculated as follows:
ICC =
σ2
P + σ2
PE
σ2
P + σ2
PE + σ2
PR + σ2
PER
There was no ‘rounds’ factor in the inter-rater repro-
ducibility of the subjective expert scores of the 18
patient descriptions, which therefore use the following
formula:
ICC =
σ2
P
σ2
P + σ2
PE
Spearman correlation coefficients were used to investi-
gate correlations between the median expert scores and
t h eo b j e c t i v ep h e n o t y p i cs e v e r i t ys c o r e s .N u m e r i c a l
weights were assigned to the items used in the objective
score according to the experts’ assessment of their clini-
cal relevance. The goal was to maximize the correlation
with the median subjective expert score and thus
achieving the best phenotypic differentiation. The level
of statistical significance was set at p < 0.05.
Results
Of the 30 items included in the first-round question-
naire (Table 1), 7 were scored as being of ‘ major impor-
tance’ by ≥ 50% of the experts and as ‘redundant’ by
none of the experts (Table 2). Nine additional items
were proposed (Table 1). The median expert scores of
the 20 case descriptions used in the second written
round ranged from 1 to 9. There was considerable varia-
tion in the expert scores for each case description (Fig-
ure 1). The difference between the highest and lowest
expert case scores ranged from 2 (for a case with a med-
ian expert score of 3) to 8 points (for a case with a med-
ian expert score of 6). The intra- and inter-observer
Table 3 The 24 items that were proposed by the individual experts during the meeting
Items Number of experts who proposed each item
#
1. Global developmental delay/cognitive decline 18
2. Age at onset of symptoms <1.5 yr 13
3. Joint stiffness/arthropathy/contractures 11
4. Kyphosis/spinal involvement 11
5. Dysostosis multiplex 10
6. Cardiac involvement: valvular disease + cardiomyopathy 10
7. Large head/frontal bossing 8
8. Hydrocephalus 7
9. Age at diagnosis <1.5 yr 7
10. Coarse facial features 6
11. Growth retardation 4
12. Hepatosplenomegaly 4
13. Corneal clouding 4
14. Pulmonary function 4
15. Obstructive sleep apnea syndrome 3
16. Hearing problems 3
17. Cervical cord compression 2
18. Carpal tunnel syndrome 2
19. Abdominal hernia 1
20. Hip dysplasia 1
21. Recurrent otitis media 1
22. Macroglossia 1
23. Early surgical intervention 1
24. Affected sibling 1
# Certain items were individually mentioned by the experts but were used as a single item in the sum score (for example, developmental delay and cognitive
decline were counted together); such items explain why the number of experts proposing a certain item occasionally exceeds the total number of experts
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respectively.
Of the 39 items identified in the ‘first written round’
(Table 1), 12 were not found in any of the 20 case
descriptions. The case scores obtained by summing the
remaining 27 items (with an item scoring 1 if it was pre-
sent and 0 otherwise) ranged from 4 to 18. The frequen-
cies of the 27 items in the 20 case descriptions ranged
from 5% to 90% (Table 4). The correlation between the
case scores from the 27 items and the median expert
scores was 0.61, p = 0.004. A significant difference in
median expert scores was found between the groups
determined by the presence or absence of 7 items
(’results, second written round’, Table 2): 1) age at onset
of symptoms (<1.5 yr) (median difference 4, p = 0.015);
2) developmental delay (median difference 4.5, p =
0.002); 3) kyphosis (median difference 5, p = 0.001); 4)
large head/frontal bossing (median difference 4, p =
0.037); 5) early diagnosis (<1.5 yr) (median difference 4,
p = 0.001); 6) dysostosis multiplex (median difference 4,
p < 0.001) and 7) coarse facial features (median differ-
ence 3.5, p = 0.012). The correlation between the
unweighted sum score of these seven items and the
median expert score was 0.91; p < 0.001.
The 24 items proposed by the individual experts are
shown in Table 3 in order of descending frequency.
During the meeting, these 24 items were compared
with the 7 items from the ‘results, second written
round’ (Table 2). Consensus was reached on including
nine of the items in the list of those considered most
important for phenotypically classifying MPS I patients
(Table 2, ‘results, consensus meeting’). For three items,
additional discussion was considered necessary in sepa-
rate working groups after the meeting. Within several
weeks after the consensus meeting, the working groups
proposed deleting three items from the final consensus
list: 1) dysostosis multiplex, 2) growth retardation, and
3) obstructive sleep apnea syndrome (OSAS). The
main reason for the exclusions was the inability of the
items to differentiate between the phenotypes. All
experts agreed with deleting these three items from
the final consensus list.
The median expert scores of the 18 case descriptions
used in the validation phase ranged from 2 to 8.5. The
inter-observer ICC of the expert scores was 0.71. Again,
there was considerable varia t i o ni nt h ee x p e r ts e v e r i t y
assessments of the case descriptions (Figure 2). The dif-
ferences between the highest and lowest expert scores
ranged from 3 (for 7 cases with median expert scores of
2.0, 2.5, 7.0, 8.0, 8.0, 8.5 and 8.5) to 8 points (for a case
with a median expert score of 7.0).
Figure 1 The expert scores per patient (for the 20 case
descriptions in the second written round, in order of
ascending median expert score).
Table 4 The 27 items occurring in the 20 case histories,
in ascending order of frequency
Items Frequency of occurrence
(%)
1. Disturbed pulmonary function 5
2. Hypertrichosis 5
3. Sternum protruded 5
4. Cardiomyopathy 10
5. Macroglossia 10
6. Growth retardation 15
7. Hypotonia in infancy 15
8. Hydrocephalus 20
9. Carpal tunnel syndrome 25
10. OSAS 25
11. Hip dysplasia 30
12. Large head/frontal bossing* 35
13. Valvular heart disease 40
14. Early diagnosis (<1.5 yr)* 40
15. Inguinal hernia 40
16. Hearing problems 40
17. Developmental delay* 55
18. Dysostosis multiplex* 55
19. Kyphosis* 65
20. Abdominal hernia 70
21. Coarse facial features* 70
22. Early onset of symptoms (<1.5 yr)* 75
23. Joint stiffness/arthropathy/
contractures
80
24. Hepatosplenomegaly 75
25. Corneal clouding 85
26. Recurrent otitis media 85
27. Recurrent upper airway infection 90
For the items marked with an*, there was a statistically significant difference
in the median expert score between the cases with and without this item.
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weighted and unweighted sum scores of the six items in
the ‘final consensus list’ and the median expert scores, it
became clear that there would always be patients whose
calculated severity score differed unacceptably from the
median expert severity score, which was considered the
‘gold standard’. For this reason, and because of the con-
siderable variability between the experts, we decided to
refrain from presenting the six criteria in a numerical
‘severity scale’.
Discussion
This consensus procedure was designed to develop a
numerical scale for assessing MPS I phenotypic severity
at diagnosis to facilitate treatment decisions and patient
communication.
Consensus was reached on a list of six items that were
considered to be most important for phenotypically clas-
sifying MPS I patients at diagnosis (Table 2, ‘final con-
sensus list’). Our consensus procedure also identified
several items generally considered to be major hallmarks
of MPS I that were nevertheless excluded from the list
of key items for the following reasons. First, the signs
and symptoms important for establishing an MPS I
diagnosis often do not differentiate between mild and
severe phenotypes, e.g., umbilical or inguinal hernias,
coarse facial features, and the presence or severity of
corneal clouding and hepatosplenomegaly. Second,
although some symptoms (e.g., hydrocephalus) are fre-
quently encountered in young patients with severe phe-
notypes, the experts did not consider their absence to
be an indicator of a mild phenotype. The ‘diagnosis at a
young age’ item was also excluded because it can be
influenced by several factors, such as diagnostic difficul-
ties or delays in seeking medical attention. The age of
o n s e to fa n yo ft h es i xk e ys i g n sa n ds y m p t o m sw a s
considered to be a more valuable indicator of phenoty-
pic severity. Finally, cognitive decline was not included
as a key item because this item can only be assessed
during follow-up (in contrast to developmental delay,
which can usually be ascertained at the time of
diagnosis).
As a result of the process of item generation, selection
and validation, we decided that constructing a reliable
numerical scale for assessing phenotypic severity in
MPS I patients was not feasible due to the remarkable
variability in the expert assessments (Figures 1 and 2),
which resulted in a large inter-observer variability. As a
result, the expert score that served as the ‘gold standard’
proved to be unreliable. Even in the patients with high
median expert scores, indicating a severe phenotype, the
individual expert scores varied considerably, with some
experts also assigning the cases intermediate scores (Fig-
ures 1 and 2). As a result of this variability among the
expert assessments, there would always be patients
(even those with the most severe MPS I-H phenotype)
whose severity scores from a system based on the six
selected items would differ considerably from the med-
ian expert score and from a severity score given by sev-
eral of the experts.
Comparably significant variability in expert severity
assessment will likely also occur for other rare diseases,
including other lysosomal storage diseases, in which
there are pleiotropic and progressive disease manifesta-
tions. Although the methods applied in our study may
be used to tease out factors related to assessing disease
severity that are comparable to the six key items that we
obtained for MPS I (Table 2), constructing a reliable
severity scale based on clinical signs and symptoms may
often be impossible.
The need for reliable and early prediction of MPS I
phenotypic severity has become even more pressing
with the development of high-throughput newborn
screening (NBS) techniques based on measuring IDUA
activity and/or immune-quantification of the IDUA pro-
tein in dried blood spots [26-28]. A severity score based
on clinical signs and symptoms will certainly not be use-
ful in this context, given that a number of signs and
symptoms will not be present in the neonatal period.
Because clinical signs and symptoms appear to be
insufficiently reliable to assess phenotypic severity at
diagnosis, other methods should be vigorously investi-
gated. Combined genotyping and biomarker analysis in
plasma and/or urine, such as the recently reported
plasma heparin cofactor II-thrombin (HCII-T) complex
and the urinary dermatan sulfate:chondroitin sulfate
Figure 2 The expert scores per patient (for the 18 case
descriptions in the validation round, in order of ascending
median expert score).
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mining disease severity in newly diagnosed MPS I
patients [2,3,29,30]
Our study has several limitations. First, the experts
differed with respect to the age, phenotype and ethnic
background of their patient experiences. These observa-
tions may have influenced their opinion of disease sever-
ity. Second, the patient information used to write the
case descriptions was gathered retrospectively. Thus,
some follow-up results were known for most of the
patients, which may have biased the data retrieval and
the description of the cases. Moreover, the information
that had been recorded in the patient files may have
been influenced by knowledge of which interventions
had (or had not) been performed. Finally, assessing phe-
notypic severity is hampered by the subjective rating of
certain items, e.g., the presence or absence of kyphosis
and frontal bossing on clinical examination, the parents’
report of the age of symptom onset and the influence of
decreased range of motion due to joint disease on per-
forming activities of daily living.
Conclusions
This robust and transparent consensus procedure did
not result in a reliable and validated numerical MPS I
severity scale. However, the process did produce a list of
six items rated by the experts as being most important
for phenotypic classification, which may be useful for
classifying newly diagnosed MPS I patients. Further stu-
dies into the possible roles of genotypes and biomarkers
as indicators of disease severity are necessary to opti-
mize clinical diagnosis and decision-making in MPS I
patients.
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